For US Healthcare Professionals only

Elitek® (rasburicase) for injection logo

Menu

Unlike Allopurinol, ELITEK® (rasburicase) IV Infusion Clears New and Existing Uric Acid1

ELITEK is an antihyperuricemic agent that has the mechanism to clear existing uric acid1

  • Allopurinol blocks the formation of new uric acid but has no mechanism to clear uric acid1

See the mechanism of action for ELITEK

Video still showing Steve (ELITEK, rasburicase) and Mary (allopurinol) with 3D molecular structures.

Not actual patients.

Mechanism of action: ELITEK vs allopurinol1,2

An image depicting an anticancer therapy lysis of cancer cells causing the release of nucleic acid catabolism, which catabolize into hypoxanthine/xanthine and how Allopurinol (xanthine oxidoase inhibitor) can block xanthine oxidase prior but have no effect on Uric acid lower solubility in urine but ELITEK rasburicase iv infusion (recombinant urate oxidase) does effect Uric acid lower solubility in urine leading to Allantoin 5-10 times more soluble in urine vs uric acid.

Consider ELITEK as your preferred choice for clearing both existing and newly formed uric acid1

Mechanism of action (MOA) Flashcard

Reference this MOA flashcard for an overview of how ELITEK works

DOWNLOAD NOW

Resource

MOA Flashcard

Coming Soon

ELITEK significantly and rapidly lowered uric acid levels compared with allopurinol3,4

96%

of adult patients who received ELITEK achieved uric acid levels ≤2 mg/dL within 4 hours after their first dose vs 0% with allopurinol4

Reduction in uric acid levels

Image showing depiction of grey and magenta color lines and gradients indicting the percentage of Plasma uric acid, mg/dL and baseline time from first dose to day 7 results with ELITEK (n=92), ELITEK + allopurinol (n=92) and allopurinol (n=01) p<0.001. The graphic has a magenta arrow indicating that ELITEK lowered uric acid levels 4 hours after the first dose. Plasma uric acid AUC from Day 1 through Day 7 was significantly lower for ELITEK and ELITEK + allopurinol than for allopurinol alone.

*Plasma uric acid AUC from Day 1 through Day 7 was significantly lower for ELITEK and ELITEK + allopurinol than for allopurinol alone.

VIEW ELITEK DOSING

References: 1. Ueng S. Rasburicase (Elitek): a novel agent for tumor lysis syndrome. Proc (Bayl Univ Med Cent). 2005;18(3):275-279. 2. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767-2778. 3. ELITEK [prescribing information]. NJ: sanofi-aventis U.S. LLC. 4. Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207-4213.

Important Safety Information

WARNING: HYPERSENSITIVITY REACTIONS, HEMOLYSIS, METHEMOGLOBINEMIA, AND INTERFERENCE WITH URIC ACID MEASUREMENTS

  • Hypersensitivity Reactions: ELITEK can cause serious and fatal hypersensitivity reactions including anaphylaxis. Immediately and permanently discontinue ELITEK in patients who experience a serious hypersensitivity reaction.
  • Hemolysis: Do not administer ELITEK to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Immediately and permanently discontinue ELITEK in patients developing hemolysis. Screen patients at higher risk for G6PD deficiency (e.g., patients of African or Mediterranean ancestry) prior to starting ELITEK.
  • Methemoglobinemia: ELITEK can result in methemoglobinemia in some patients. Immediately and permanently discontinue ELITEK in patients developing methemoglobinemia.
  • Interference with Uric Acid Measurements: ELITEK enzymatically degrades uric acid in blood samples left at room temperature. Collect blood samples in prechilled tubes containing heparin and immediately immerse and maintain sample in an ice water bath. Assay plasma samples within 4 hours of collection.

Contraindictions

ELITEK is contraindicated in patients with a history of anaphylaxis or severe hypersensitivity to rasburicase or in patients with development of hemolytic reactions or methemoglobinemia with rasburicase. ELITEK is contraindicated in individuals deficient in glucose-6-phosphate dehydrogenase (G6PD).

Adverse Reactions

Most common adverse reactions (incidence ≥20%), when used concomitantly with anticancer therapy, are vomiting, nausea, fever, peripheral edema, anxiety, headache, abdominal pain, constipation, diarrhea, hypophosphatemia, pharyngolaryngeal pain, and increased alanine aminotransferase.

Use in Specific Populations

  • Pregnancy: Consider the benefits and risks of ELITEK and possible risks to the fetus when prescribing ELITEK to a pregnant woman
  • Lactation: Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with ELITEK and for 2 weeks after the last dose

Indication

ELITEK is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.

Limitation of use: ELITEK is indicated only for a single course of treatment.

Click here for Full Prescribing Information for Elitek.
Click here for information on Sharps Medical Waste Disposal.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.

Important Safety Information

Indication

ELITEK and Sanofi are registered trademarks of Sanofi or an affiliate. All the other trademarks above are the property of their respective owners, who have no affiliation or relationship with Sanofi. MAT-US-2020414-v3.0-03/2025

Back to top
sanofi_campus_logo
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContact
© 2025 Sanofi. All rights reserved.